RYVU Therapeutics S.A.

Report Publication Announcement • Dec 19, 2025

Report Content Receipt of a notification pursuant to Article 69 of the Act on PublicOffering

The Management Board of Ryvu Therapeutics S.A., with its registeredoffice in Kraków (the "Company"), hereby informs that on December 19,2025 it received notifications from the Company's shareholder Mr. PawełPrzewięźlikowski and Benevora Family Foundation in organization,prepared pursuant to Article 69(1)(1) and Article 69a(1)(3) of the Actof 29 July 2005 on Public Offering, the Conditions Governing theIntroduction of Financial Instruments to an Organized Trading System andPublic Companies.

According to the content of the received notifications, as a result of adonation of the Company's shares made by Mr. Paweł Przewięźlikowski,which the Company reported in current report No. 31/2025 dated December10, 2025, the entire block of the Company's shares previously held byMr. Paweł Przewięźlikowski was transferred to Benevora Family Foundationin organization. Mr. Paweł Przewięźlikowski's share in the total numberof votes at the General Meeting of the Company, held indirectly througha closely related entity, i.e. Benevora Family Foundation inorganization, has not changed and amounts to 27.54%.

The full text of the notification is attached to this current report.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.